Signature of a 15.0 million financing deal with the European Investment Bank
30/11/2020 – AB Science announces the signature of a 15.0 million financing deal with the European Investment Bank to support clinical development of masitinib in Covid-19
Equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACT
16/11/2020 – AB Science secures equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACT
Financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares
29/10/2020 – AB Science announces a financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares
Positive top-line Phase 3 results for oral masitinib in severe asthma
20/10/2020 – AB Science announces positive top-line Phase 3 results for oral masitinib in severe asthma
Results from masitinib study AB07015 in severe asthma selected for presentation at an American Thoracic Society symposium
13/10/2020 – Results from masitinib study AB07015 in severe asthma selected for presentation at an American Thoracic Society (ATS) symposium held on October 16, 2020
First half of 2020 results
30/09/2020 – AB Science reports its revenues for the first half of 2020
AB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World’s Largest Multiple Sclerosis Research Conference
14/09/2020 – AB Science presents Phase 2B/3 study results in Progressive Multiple Sclerosis at the world’s largest Multiple Sclerosis research conference
AB Science to present results from its AB07015 study in severe asthma at the annual European Respiratory Society International Congress
08/09/2020 – AB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congres
AB Science to present results from its AB07002 study in progressive forms of MS at MSVirtual2020
07/09/2020 – AB Science to present results from its Phase 2B/3 AB07002 study in progressive forms of multiple sclerosis at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting
New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro
02/09/2020 – New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in-vitro and is a promising candidate for treating COVID-19